Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Revenue of Aldeyra Therapeutics, Inc. (ALDX)
Revenue in 2023 (TTM): $
According to Aldeyra Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Aldeyra Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-262,780 | $-35,208,295 | $-37,542,510 | $-37,542,510 |
| 2022 | $ | $-258,707 | $-60,071,831 | $-62,024,636 | $-61,369,285 |
| 2021 | $ | $-264,180 | $-55,769,993 | $-57,776,274 | $-59,254,195 |
| 2020 | $ | $-56,221 | $-36,072,575 | $-38,032,994 | $-37,553,729 |
| 2019 | $ | $-96,305 | $-61,436,653 | $-62,136,804 | $-60,826,831 |
| 2018 | $ | $-71,003 | $-38,675,450 | $-38,893,245 | $-38,893,245 |
| 2017 | $ | $-37,849 | $-22,189,287 | $-22,340,590 | $-22,340,589 |
| 2016 | $ | $-35,792 | $-18,558,149 | $-18,699,450 | $-18,699,450 |
| 2015 | $ | $-18,778 | $-11,959,203 | $-12,090,287 | $-12,090,287 |
| 2014 | $ | $ | $-4,942,016 | $-5,187,259 | $-5,187,259 |
| 2013 | $ | $ | $13.22 M | $13.06 M | $13.06 M |
| 2012 | $ | $ | $-22,728,763 | $-23,074,515 | $-23,074,515 |
| 2011 | $ | $ | $-2,096,539 | $-2,378,064 | $-2,378,064 |